会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • PRODUCTION METHOD FOR HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE, PRODUCTION INTERMEDIATE THEREOF, AND CRYSTAL
    • 用于生产HETEROARYLCARBOXYLSÄUREESTERDERIVATS,生产及其中间体和晶体
    • EP3118197A1
    • 2017-01-18
    • EP15761578.2
    • 2015-03-11
    • EA Pharma Co., Ltd.
    • YAMADA, TatsuhiroTATARA, AkinoriTAKASHITA, RyutaKODAMA, RihoOOKUMA, Kazutaka
    • C07D333/40
    • C07D333/40
    • Provision of a production method of compound (VI) useful as a therapeutic drug for diabetes, its intermediate, and its crystal. A production method of compound (VI) or a salt thereof, including (d) a step of reacting compound (II) with an acid halogenating agent to give an acid halide, (e) a step of reacting the acid halide with compound (IV) in the presence of a base, and crystallizing compound (V) or a salt thereof from the reaction system, and (f) a step of subjecting the compound (V) to reductive deprotection in the presence of a metal catalyst, and crystallizing compound (VI) or a salt thereof from the reaction system:




      wherein R5 is an aralkyl group optionally having a substituent(s), an aralkyloxymethyl group optionally having a substituent(s), or a heteroarylalkyl group optionally having a substituent(s).
    • 作为治疗药物用于治疗糖尿病,其中间体,和其结晶有用的化合物(VI)的制造方法的规定。 化合物的制造方法(VI)或其盐,包括(d)与在酸卤化剂反应化合物(II),得到酰卤的步骤,(E)使与化合物酰基卤的步骤(IV )在碱和结晶化化合物(V)或从反应体系或其盐,和(f)使化合物(V)在金属催化剂的存在下进行还原脱保护,和结晶化化合物的步骤的存在 (VI)或从反应体系或其盐:worin R5为任选具有取代基(一个或多个)的芳烷基,芳烷到基,任选具有取代基(一个或多个),或任选具有取代基(一个或多个)杂芳基烷基。